San Diego, Calif – April 14, 2020 — Crown Bioscience has announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately. Dr. Wery will also serve as chief technology officer (CTO) for JSR Life Sciences, LLC.
JSR acquired Crown Bioscience in 2018 to expand their life science portfolio to serve the preclinical market. In this new role, Dr. Wery will lead the JSR Life Sciences companies’ collaborative efforts to identify strategic synergies and develop innovative technologies, platforms and tools for the drug and biomarker research communities. This leadership change ensures enhanced collaboration between Crown Bioscience and the JSR Life Sciences family of companies to expand their already significant life sciences footprint.
Crown Bioscience is also pleased to announce the appointment of Armin Spura, PhD to succeed Dr. Wery as chief executive officer, effective from April 1, 2020. As CEO, Dr. Spura will drive the global corporate strategy for Crown Bioscience, further strengthening the company’s position at the forefront of preclinical research services across oncology, metabolic disease and inflammation.
“I have embraced and enjoyed the varied challenges inherent in growing Crown Bioscience into a world-leading, global preclinical CRO,” said Dr. Wery. “It is now the right time to hand over the reins to Armin to lead the company into the next period of innovation and growth”.
Crown Bioscience is a leading contract research organization (CRO) in both the drug discovery and biomarker discovery arenas with a range of innovative product portfolios available across sites in Asia, the US and Europe. Crown Bioscience currently employs more than 700 people.
“I am delighted to join Crown Bioscience and to continue the company’s pioneering approach to developing new solutions for our clients,” said Dr. Spura. “I believe Crown Bioscience is uniquely innovative within the preclinical CRO arena, and that innovation will remain a core to our identity, growth and market leadership position.”
Crown Bioscience Inc.